105 related articles for article (PubMed ID: 38772678)
1. Severe enterovirus infections in patients with immune-mediated inflammatory diseases receiving anti-CD20 monoclonal antibodies.
Martin de Frémont G; Chabrolles H; Mirand A; L'Honneur AS; Mélé N; Dunogue B; Boutboul D; Farhat M; Hachulla E; Lazrek M; Rieu V; Mathian A; Chaussade H; Ruet A; Burrel S; Coury-Lucas F; Schuffenecker I; Lemaignen A; Stefic K; le Besnerais M; Carrette M; Mouthon L; Avettand-Fenoel V; Terrier B; Hadjadj J
RMD Open; 2024 May; 10(2):. PubMed ID: 38772678
[TBL] [Abstract][Full Text] [Related]
2. Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy.
Palacios T; Bartelt L; Scheld W; Lopes MB; Kelting SM; Holland S; Lipkin WI; Quan PL; Borish L; Lawrence M
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):148-50. PubMed ID: 26048250
[No Abstract] [Full Text] [Related]
3. Enterovirus 71 meningoencephalitis complicating rituximab therapy.
Ahmed R; Buckland M; Davies L; Halmagyi GM; Rogers SL; Oberste S; Barnett MH
J Neurol Sci; 2011 Jun; 305(1-2):149-51. PubMed ID: 21444094
[TBL] [Abstract][Full Text] [Related]
4. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.
Sacco KA; Abraham RS
Immunotherapy; 2018 Jun; 10(8):713-728. PubMed ID: 29569510
[TBL] [Abstract][Full Text] [Related]
5. Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab.
Kapadia RK; Gill CM; Baca C; McMenamin C; Kannappan A; Niehaus WN; Tyler KL; Pastula DM; Piquet AL
J Neuroimmunol; 2021 Sep; 358():577639. PubMed ID: 34214953
[TBL] [Abstract][Full Text] [Related]
6. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
10. Disseminated Enteroviral Infection Associated with Obinutuzumab.
Dendle C; Gilbertson M; Korman TM; Golder V; Morand E; Opat S
Emerg Infect Dis; 2015 Sep; 21(9):1661-3. PubMed ID: 26291712
[TBL] [Abstract][Full Text] [Related]
11. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan.
Yang KD; Yang MY; Li CC; Lin SF; Chong MC; Wang CL; Chen RF; Lin TY
J Infect Dis; 2001 Mar; 183(6):850-6. PubMed ID: 11237800
[TBL] [Abstract][Full Text] [Related]
12. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
[TBL] [Abstract][Full Text] [Related]
13. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
Pers YM; Jorgensen C
Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
[TBL] [Abstract][Full Text] [Related]
14. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
Quartier P; Tournilhac O; Archimbaud C; Lazaro L; Chaleteix C; Millet P; Peigue-Lafeuille H; Blanche S; Fischer A; Casanova JL; Travade P; Tardieu M
Clin Infect Dis; 2003 Feb; 36(3):e47-9. PubMed ID: 12539090
[TBL] [Abstract][Full Text] [Related]
15. The anti-CD20 antibody rituximab reduces the Th17 cell response.
van de Veerdonk FL; Lauwerys B; Marijnissen RJ; Timmermans K; Di Padova F; Koenders MI; Gutierrez-Roelens I; Durez P; Netea MG; van der Meer JW; van den Berg WB; Joosten LA
Arthritis Rheum; 2011 Jun; 63(6):1507-16. PubMed ID: 21400475
[TBL] [Abstract][Full Text] [Related]
16. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies.
Pedersen AE; Jungersen MB; Pedersen CD
Immunology; 2011 Jun; 133(2):239-45. PubMed ID: 21426340
[TBL] [Abstract][Full Text] [Related]
17. Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection.
You L; Chen J; Cheng Y; Li Y; Chen YQ; Ying T; Turtle L; Yu H
PLoS Pathog; 2023 Jun; 19(6):e1011420. PubMed ID: 37262073
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract][Full Text] [Related]
20. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
